About P&T JournalContacts:
Statement of Purpose
Guidelines for Authors
In addition to blogging and featuring their own Web sites, some drug companies are cautiously entering the Twitter community as they seek additional outlets for reaching their audience.
Warfarin is commonly used to prevent and treat thromboembolic disease, but it is difficult to administer at the correct dose, primarily because of variations in patient responses. With new advances in medicine, it may be possible to tailor pharmacotherapy based on a patient’s genetic profile.
Jiayi Li, MD; Shan Wang, PharmD, RPh; Joseph Barone, PharmD Candidate; and Brian Malone, MS, RPh
Regulation, Distribution, Evaluation, and Related Controversies
Although one of the FDA’s main goals is to protect consumers from unsafe products, the off-label use of prescription drugs is quite common. The history and debate regarding the distribution of off-label drug information and the FDA’s inability to limit non-approved uses of pharmaceuticals are reviewed.
C. Lee Ventola, MS
This conference covered requirements for FDA approval of medical devices, including classifications, premarket submissions, and 510(k) reviews. Investigational devices and humanitarian use devices are also presented.
Marvin M. Goldenberg, PhD, RPh, MS
Some of the topics covered at the ADA sessions included therapies for achieving glycemic control in patients with type-2 diabetes. The EULAR meeting featured discussions of agents such as abatacept (Orencia) and tumor necrosis factor inhibitors for rheumatoid arthritis.
David B. Nash, MD, MBA, explains why he thinks the Obama administration’s proposed government-sponsored health insurance company might be just a political “straw man.”
David B. Nash, MD, MBA
Matthew Grissinger, RPh, FASCP, presents the dangers of the improper use of magnesium sulfate in obstetrical practice.
Matthew Grissinger, RPh, FASCP
Opportunities for Congress, Liabilities for Pharmacies
Stephen Barlas describes new government rules that might force pharmacies to take back unused and expired prescription drugs, including controlled substances, for proper disposal.
From Alimta to Zyban, P&T presents the latest studies about FDA approvals, new indications, recalls, and industry updates.
Prasugrel (Effient), an Adenosine Diphosphate Receptor Antagonist for the Treatment of Acute Coronary Syndrome
Prasugrel (Effient), an antiplatelet agent, is now approved for patients with acute coronary syndrome.
Miren E. Jauregui, PharmD, Ogochukwu U. Umejei, PharmD, and Martin P. Cruz, PharmD, CGP, BCPP